Where can I buy shares of Ubx?
Mar 26, 2022 · Unity Biotechnology's stock was trading at $5.39 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, UBX shares have decreased by 81.0% and is now trading at $1.0250. View which stocks have been most impacted by COVID-19.
When did Ubx go public?
Mizuho upgraded Unity Biotechnology Inc (NASDAQ: UBX) to Buy from Neutral with a price target of , up from $5 after Unity announced longer-term Phase 1 …
Why did Mizuho upgrade Unity Biotechnology Inc (Ubx) stock?
Apr 01, 2022 · Real-time trade and investing ideas on Unity Biotechnology UBX from the largest community of traders and investors.
Should you buy Unity Biotechnology (UBT) stock?
Apr 08, 2022 · Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and …
Is UBX a good stock to invest?
Valuation metrics show that UNITY Biotechnology, Inc. may be overvalued. Its Value Score of D indicates it would be a bad pick for value investors. The financial health and growth prospects of UBX, demonstrate its potential to underperform the market.
Will UBX stock go up?
During the day the stock fluctuated 5.83% from a day low at $1.03 to a day high of $1.09....Predicted Opening Price for Unity Biotechnology Inc. of Monday, April 18, 2022.Fair opening price April 18, 2022Current price$1.05$1.04 (Undervalued)
Who owns stock in UBX?
Top 10 Owners of UNITY Biotechnology IncStockholderStakeShares ownedMarshall Wace LLP1.55%891,977GSA Capital Partners LLP1.21%696,115BlackRock Fund Advisors0.98%563,747Millennium Management LLC0.96%551,9086 more rows
What is the forecast for UBX stock?
Stock Price Forecast The 6 analysts offering 12-month price forecasts for UNITY Biotechnology Inc have a median target of 6.50, with a high estimate of 12.00 and a low estimate of 4.00. The median estimate represents a +534.15% increase from the last price of 1.02.
Why is UBX stock dropping?
The reason for Unity's stock value falling is directly tied to the results of its second-phase clinical results for UBX0101. The drug is meant to treat moderate to severe osteoarthritis (OA) in the knee.
What does unity biotech do?
At UNITY we are developing therapeutics to slow, halt, or reverse diseases of aging. Age-related diseases, such as vision loss and cognitive decline, cause considerable economic, personal, and societal burden for individuals, their families, and broader communities.
How many patents does unity biotechnology have?
140 patentsWe are an innovative biotechnology company focused on developing novel insights into the biology of age-related diseases. Our current patent portfolio consists, on a worldwide basis, of more than 140 patents and pending applications in the United States and in foreign jurisdictions.
Is unity biotech a good buy?
Unity Biotechnology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
What stock is TAAS?
A TaaS stock is a financial asset sold by a public company within the TaaS industry, such as Uber (NYSE: UBER), Lift (NYSE: LYFT), Yandex (NYSE: YNDX), or Dominos Pizza (NYSE: DPZ)....TaaS industry and TaaS Stock Predictions for 2021.CompanyStock Price Fluctuation 1/1/ 2021 – 5/27/2021Facedrive$10.37 – $47.463 more rows
Who invested in unity biotechnology?
In the last 10 years, Unity has attracted investors like Jeff Bezos, Peter Thiel and Arch Venture Partners' Bob Nelsen — raking in more than $200 million in funding.
Is Unity Biotechnology a buy right now?
5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Unity Biotechnology in the last twelve months. There are...
How has Unity Biotechnology's stock price been impacted by COVID-19 (Coronavirus)?
Unity Biotechnology's stock was trading at $5.39 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Hea...
Are investors shorting Unity Biotechnology?
Unity Biotechnology saw a increase in short interest in February. As of February 15th, there was short interest totaling 1,170,000 shares, an incre...
When is Unity Biotechnology's next earnings date?
Unity Biotechnology is scheduled to release its next quarterly earnings announcement on Tuesday, March 22nd 2022. View our earnings forecast for U...
How were Unity Biotechnology's earnings last quarter?
Unity Biotechnology, Inc. (NASDAQ:UBX) issued its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.30) EPS for the...
What price target have analysts set for UBX?
5 brokers have issued twelve-month price objectives for Unity Biotechnology's stock. Their forecasts range from $4.00 to $12.00. On average, they e...
Who are Unity Biotechnology's key executives?
Unity Biotechnology's management team includes the following people: Anirvan Ghosh , Chief Executive Officer & Director Nathan Guz , Vice Presid...
Who are some of Unity Biotechnology's key competitors?
Some companies that are related to Unity Biotechnology include Redx Pharma (REDX) , EKF Diagnostics (EKF) , Theratechnologies (THERF) , Xilio T...
What other stocks do shareholders of Unity Biotechnology own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Unity Biotechnology investors own include NIO (NIO) , Ins...
Is Unity Biotechnology a buy right now?
What stocks does MarketBeat like better than Unity Biotechnology?
3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Unity Biotechnology in the last year. There are currently 1 hold rating and 2 buy ratings for the stock.
When is Unity Biotechnology's next earnings date?
Wall Street analysts have given Unity Biotechnology a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Unity Biotechnology wasn't one of them.
How were Unity Biotechnology's earnings last quarter?
Unity Biotechnology is scheduled to release its next quarterly earnings announcement on Wednesday, November 3rd 2021.#N#View our earnings forecast for Unity Biotechnology.
How has Unity Biotechnology's stock price been impacted by COVID-19 (Coronavirus)?
Unity Biotechnology, Inc. (NASDAQ:UBX) released its quarterly earnings results on Monday, August, 9th. The company reported ($0.32) earnings per share (EPS) for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.32).#N#View Unity Biotechnology's earnings history.
What price target have analysts set for UBX?
Unity Biotechnology's stock was trading at $5.39 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, UBX shares have decreased by 38.0% and is now trading at $3.34.#N#View which stocks have been most impacted by COVID-19.
Who are some of Unity Biotechnology's key competitors?
3 analysts have issued 12-month price objectives for Unity Biotechnology's shares. Their forecasts range from $5.00 to $12.00. On average, they anticipate Unity Biotechnology's stock price to reach $7.67 in the next year.
Unity Biotech's UBX1325 Shows Initial Efficacy With Improved Vision, Structure In Vascular Eye Disease
Some companies that are related to Unity Biotechnology include Semler Scientific (SMLR), Vapotherm (VAPO), AxoGen (AXGN), Xenon Pharmaceuticals (XENE), Eliem Therapeutics (ELYM), Aligos Therapeutics (ALGS), Silverback Therapeutics (SBTX), Adagene (ADAG), Pharming Group (PHAR), Extendicare (EXE), Collegium Pharmaceutical (COLL), AnaptysBio (ANAB), Pulse Biosciences (PLSE), TCR2 Therapeutics (TCRR) and PAVmed (PAVM).#N#View all of UBX's competitors..
Is Unity Biotechnology, Inc. (UBX) A Good Stock To Buy?
Unity Biotechnology Inc (NASDAQ: UBX) has announced positive data from its Phase 1 safety study of UBX1325 in patients with diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD) for whom anti-VEGF therapy was no longer considered beneficial.
Is Unity Biotechnology, Inc. (NASDAQ:UBX) Popular Amongst Institutions?
We at Insider Monkey have gone over 866 13F filings that hedge funds and prominent investors are required to file by the SEC. The 13F filings show the funds’ and investors’ portfolio positions as of March 31st. In this article, we look at what those funds think of Unity Biotechnology, Inc. (NASDAQ:UBX) based on that […]
Are Options Traders Betting on a Big Move in Unity Biotechnology (UBX) Stock?
Every investor in Unity Biotechnology, Inc. ( NASDAQ:UBX ) should be aware of the most powerful shareholder groups...
The Daily Biotech Pulse: Ziopharm To Start Blood Cancer Study, Chemocentryx & Soligenix Slump On Adverse Clinical Trial Outcomes
Investors need to pay close attention to Unity Biotechnology (CRMD) stock based on the movements in the options market lately.
Is Unity Biotechnology (UBX) A Good Stock To Buy Now?
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 20) * Acceleron Pharma Inc (NASDAQ: XLRN) * Adaptive Biotechnologies Corp (NASDAQ: ADPT) * Allakos Inc (NASDAQ: ALLK) * Alpine Immune Sciences Inc (NASDAQ: ALPN) * AtriCure Inc.
Company Profile
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn’t the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]
Analyst Opinions
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate include UBX1325, which is Phase I clinical trial for the…
Research Reports
The Equity Summary Score is an accuracy-weighted sentiment derived from the ratings of independent research providers on Fidelity.com. It uses the past relative accuracy of the providers in determining the emphasis placed on any individual opinion. Learn More....
Signals & Forecast
This generated report* compiles independent, third-party information highlighting key fundamental and technical data, analyst opinions, stock price movement, earnings data, and industry comparisons. Available only to Fidelity customers.
Support, Risk & Stop-loss
There are mixed signals in the stock today. The Unity Biotechnology Inc. stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average.
Is Unity Biotechnology Inc. stock A Buy?
Unity Biotechnology Inc. finds support from accumulated volume at $3.64 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
Price Target and Analyst Ratings
Unity Biotechnology Inc. holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.
UBX Stock Trend
On July 28, 2021 "HC Wainwright" gave "$12.00" rating for UBX. The price target was set to $3.82.
UNITY Biotechnology, Inc. (UBX)
The stock lies in the lower of a wide and falling trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at $3.59 is broken, it will firstly indicate a stronger fall rate.
Style Scorecard
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Chart for UBX
The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.
UBX earnings per share forecast
UNITY Biotechnology Inc. develops therapeutics which prevents, halts and reverses various diseases. The company's product portfolio includes UBX101, is designed to treat musculoskeletal disease with an initial focus on osteoarthritis. UNITY Biotechnology Inc. is based in California, United States.
UBX revenue forecast
What is UBX 's earnings per share in the next 3 years based on estimates from 4 analysts?
The development-stage biopharma announced disappointing results from a clinical trial
What is UBX 's revenue in the next 3 years based on estimates from 1 analysts?
What happened
Maxx has been a contributor to Fool.com since 2013. He graduated from the State University of New York College of Environmental Science and Forestry (2012) with a Bachelor of Science in Bioprocess Engineering and from Carnegie Mellon University (2016) with a Master of Science in Materials Science & Engineering.
So what
Shares of Unity Biotechnology ( NASDAQ:UBX) fell over 63% today after the company announced disappointing results from a clinical trial involving its lead drug candidate, UBX0101.
Now what
Unity Biotechnology is developing a drug pipeline based on the idea that clearing senescent cells, or cells that stop dividing, can help to treat or reverse age-related diseases. The idea has been around for decades and has begun to gain traction in recent years with new developments in living technologies.
